Anticorps Polyclonal de lapin anti-SUCLG2

• Phare
• Validé par KD/KO

SUCLG2 Polyclonal Antibody for WB, IHC, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF, IP, ELISA

Conjugaison

Non conjugué

Publications(5)

Avis (1)

N° de cat : 14240-1-AP

Synonymes

EC:6.2.1.4, G BETA, G-SCS, GTPSCS, GTP-specific succinyl-CoA synthetase subunit beta

---

Galerie de données de validation

• 

  WB analysis using 14240-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 14240-1-AP (SUCLG2 antibody) at dilution of 1:15000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of mouse kidney using 14240-1-AP

  IP result of anti-SUCLG2 (IP:14240-1-AP, 4ug; Detection:14240-1-AP 1:600) with mouse kidney tissue lysate 4800ug.

• 

  IHC staining of human colon cancer using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of mouse kidney using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse kidney tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human gliomas using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human gliomas slide using 14240-1-AP (SUCLG2 Antibody) at dilution of 1:25.

• 

  IHC staining of human gliomas using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human gliomas slide using 14240-1-AP (SUCLG2 Antibody) at dilution of 1:25.

---

Applications testées

• Résultats positifs en WB: cellules COLO 320, cellules HepG2, tissu hépatique de rat, tissu hépatique de souris
• Résultats positifs en IP: tissu rénal de souris
• Résultats positifs en IHC: tissu de cancer du côlon humain, tissu de gliome humain, tissu rénal de souris; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 4 publications below
• IHC: See 2 publications below
• IF: See 1 publications below
• IP: See 1 publications below

Informations sur le produit

14240-1-AP cible SUCLG2 dans les applications de WB, IHC, IF, IP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: rat, Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: SUCLG2 Protéine recombinante Ag5495
• Nom complet: succinate-CoA ligase, GDP-forming, beta subunit
• Masse moléculaire calculée: 47 kDa
• Poids moléculaire observé: 47 kDa
• Numéro d’acquisition GenBank: BC047024
• Symbole du gène: SUCLG2
• Identification du gène (NCBI): 8801
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

SUCLG2, encodes a GTP-specific beta subunit of succinyl-CoA synthetase. Succinyl-CoA synthetase catalyzes the reversible reaction involving the formation of succinyl-CoA and succinate. The deficiency of SUCLG2 represents an encephalomyopathic form of mtDNA depletion syndromes (PMID:30470562). Mutated SUCLG1 causes mislocalization of SUCLG2 protein, morphological alterations of mitochondria and an early-onset severe neurometabolic disorder. SUCLG2 is mainly expressed in liver, kidney, heart (PMID: 9765291).

Publications

Species	Application	Title
human	WB,IP,IHC,IF	Adv Sci (Weinh); SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma; Authors - Qifan Hu
human	WB	Oncogene; Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.; Authors - Susumu Kohno ; KO Validated
human	IHC	Clin Cancer Res; Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics; Authors - Xiaoqi Peng
human	WB	Arthritis Rheumatol; Mitochondrial control of proteasomal Psmb5 drives the differentiation of tissue-resident memory T cells in patients with rheumatoid arthritis; Authors - Tong Wu
rat	WB	Biochim Biophys Acta Mol Basis Dis; SIRT5 mediated succinylation of SUCLA2 regulates TCA cycle dysfunction and mitochondrial damage in pancreatic acinar cells in acute pancreatitis; Authors - Wenbin Liu

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.

---

FH

Jun (Verified Customer) (05-08-2025)

Works well for WB, IP and IF

• Applications: Western Blot, Immunoprecipitation
• Primary Antibody Dilution: 1:1000 for WB; 1ug for IP
• Cell Tissue Type: C2C12 cells

{{ptg:RelatedPrimaryAntibodies}}